Key points from article :
Nathan Cheng looks at the companies mentioned in the recent Nature article on senescent cell therapies.
Unity Biotechnology
- repurposing small molecule cancer drugs
- only senolytics company to go public to date
Senolytic Therapeutics
- small molecule drug, nanoparticle delivery, monoclonal antibody (immunotherapy), prodrugs
- also pursuing senomorphic therapies
- daughter company of Life Biosciences
Rubedo Life Sciences
- small molecule drugs
- minimal details on their development timeline
Oisin Biotechnologies
- developing a novel flexible gene therapy platform
- gene delivery platform technology is cheap, flexible, and scalable
Cleara Biotech
- preclinical
- focussing on an improved version of FOXO4-DRI peptide
FoxBio
- joint venture company between Juvenescence and Antoxerene
- small molecule drugs that target the FOXO4-p53 interaction
Numeric Biotech
- focussing on neuroinflammatory and autoimmune diseases
Siwa Therapeutics
- monoclonal antibody that targets cells that have higher levels of glycolysis
- increase muscle mass in a naturally aged mouse model
Atropos Therapeutics
- FATES senescence suppressor / stimulator screening platform
Deciduous Therapeutics
- immune modulators
- still in stealth mode, no timeline on clinical trials
Dorian Therapeutics
- developing USP16-inhibitor senoblocker
- also improves cell viability in CAR-T cell therapy
Rejuversen -
- developing a monoclonal antibody targeting PD-L2 in order to recruit the immune system to clear senescent cells that promote cancer relapse or metastasis
Oncosence
- two-step therapy that first induces senescence in cancer cells followed by a senolytic to clear them
Senisca
- modulating RNA splicing factors that become dysregulated with age
- lead indication is Idiopathic Pulmonary Fibrosis (IPF)
